Novo Nordisk cuts price of anti-obesity drug Wegovy in India by 37%

Danish drugmaker Novo Nordisk on Tuesday said it has reduced the price of its obesity medication Wegovy in India by 37%, as it seeks to make the once-weekly injection more accessible amid rising demand for anti-obesity drugs.

The company said the starting dose of Wegovy (0.25 mg) will now be available at an effective weekly price of ₹2,712, down from ₹4,336 earlier.

Wegovy, launched across India in June 2025, is available in five dose strengths and is the first and only obesity drug in the country indicated for both chronic weight management and reduction in cardiovascular risk.

“Patient centricity is the cornerstone of Novo Nordisk,” said Vikrant Shrotriya, managing director of Novo Nordisk India. “Ever since the launch of this innovative chronic weight management medication, we have dedicatedly worked towards making it accessible to the maximum number of people living with overweight or obesity in India,” he added.

Novo Nordisk, the global leader in GLP-1-based therapies, is among a growing list of multinational drugmakers vying for a share of India’s nascent but fast-expanding anti-obesity drug market.

India’s obesity drug market, valued at around ₹3,000–₹3,500 crore in 2024, is projected to surge to ₹25,000 crore by 2030 as obesity rates rise and treatment perceptions shift from lifestyle modification to medical management, according to the IMARC Group.

India has seen a steady rise in obesity rates. As per the National Family Health Survey (2019–21), 24% of Indian women and 23% of men are overweight or obese, while the share of overweight children under five has increased from 2.1% in 2015–16 to 3.4%.

Novo Nordisk’s price cut comes amid growing competition from rival global pharmaceutical firms preparing to introduce similar drugs in India’s weight-loss segment.